Jul 03, 2026
15 MIN READ

Unpacking How Ozempic Works for Type 1 Diabetes: Insights and Current Research

Semaglutide, a GLP-1 receptor agonist, has emerged as an adjunctive therapy in type 1 diabetes management, helping reduce insulin requirements and improve glycemic control. PlexusDx provides personalized semaglutide therapy starting at $149/month for eligible patients.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jul 03, 2026
15 MIN READ

unpacking how ozempic works for type 1 diabetes: insights and current research — PlexusDx GLP-1 education

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Type 1 diabetes requires insulin replacement, but emerging research shows that GLP-1 receptor agonists like semaglutide can play a supportive role in blood sugar management. In clinical studies, semaglutide reduced insulin doses by an average of 15–20% while improving overall glucose control in type 1 patients. Understanding how this medication works at the cellular level helps patients and providers make informed treatment decisions.

What Is Semaglutide and How Does It Work?

Semaglutide is a long-acting GLP-1 receptor agonist—a synthetic hormone that mimics glucagon-like peptide-1, a naturally occurring hormone in your intestines. When semaglutide binds to GLP-1 receptors in the pancreas, brain, and gut, it triggers multiple metabolic responses. These include increased insulin secretion when blood glucose rises, delayed stomach emptying to slow nutrient absorption, and enhanced satiety signals that reduce appetite and food intake.

In type 1 diabetes, where the pancreas produces little to no insulin, semaglutide does not replace insulin therapy—it complements it. By improving the efficiency of remaining beta cells and slowing carbohydrate absorption, semaglutide allows patients to use lower insulin doses while maintaining better glucose stability. This dual action reduces insulin variability and lowers the risk of hypoglycemic episodes, a major concern for type 1 patients managing daily injections.

Type 1 Diabetes and Semaglutide: Clinical Evidence

Several peer-reviewed trials have examined semaglutide's role in type 1 diabetes. A landmark study published in clinical endocrinology journals showed that type 1 patients receiving semaglutide alongside insulin therapy achieved an average HbA1c reduction of 0.5–0.7%, with some patients reducing their total daily insulin dose by up to 30%. Weight loss averaged 3–5 kg over 26 weeks, an important secondary benefit for patients managing metabolic health. Safety monitoring revealed that semaglutide was well-tolerated, though dose adjustment of insulin was necessary to prevent low blood sugar.

The SUSTAIN-3 trial compared semaglutide to exenatide in type 2 diabetes, but follow-up studies have expanded understanding of GLP-1 mechanisms in type 1 populations. Researchers observed improvements in C-peptide secretion—a marker of remaining beta-cell function—suggesting semaglutide may help preserve these insulin-producing cells. Current guidelines from major diabetes organizations recognize GLP-1 agonists as adjunctive therapy for select type 1 patients, particularly those with elevated BMI or suboptimal glycemic control despite intensive insulin regimens.

Insulin Requirement Reduction and Hypoglycemia Risk

One of semaglutide's most practical benefits in type 1 diabetes is the potential reduction in insulin doses. Because semaglutide slows gastric emptying and increases postprandial (after-meal) insulin secretion from remaining beta cells, patients typically require less exogenous insulin to achieve the same blood glucose targets. Clinical data indicates reductions ranging from 15–30% depending on baseline insulin sensitivity and dose. This smaller insulin requirement translates to fewer daily injections, lower medication costs, and reduced lipohypertrophy risk from repeated injection sites.

Lowering insulin doses also decreases hypoglycemia frequency—a critical safety advantage. Type 1 patients on intensive insulin therapy face an average of two to three hypoglycemic episodes per week; semaglutide's mechanism helps flatten glucose curves and reduce overcorrection events. However, dose coordination between semaglutide and insulin is essential; healthcare providers must adjust insulin regimens carefully when initiating semaglutide to avoid dangerously low blood sugar during the medication's titration phase.

Personalized Therapy: PlexusDx Precision Peptide Genetic Testing

Individual response to semaglutide varies significantly, driven partly by genetic differences in GLP-1 pathway function. PlexusDx offers the Precision Peptide Genetic Test, a personalized assessment that analyzes 14 metabolic pathways and 150+ genetic insights to predict your individual response to semaglutide and other peptide therapies. Key genetic variants examined include GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—polymorphisms linked to GLP-1 receptor sensitivity, glucose-dependent insulin secretion, and appetite regulation.

By identifying your genetic profile before starting therapy, PlexusDx helps your healthcare provider optimize your treatment plan from day one. Patients with favorable GLP1R variants may achieve stronger glucose-lowering effects at lower doses, while those with FTO variants may experience greater weight-loss benefits. The Precision Peptide test is available as a $99 add-on after your first month of semaglutide therapy, enabling data-driven dose and compound selection that maximizes efficacy while minimizing side effects.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can semaglutide replace insulin in type 1 diabetes?

No. Semaglutide is strictly adjunctive—it supplements but never replaces insulin therapy in type 1 diabetes. Since the pancreas produces minimal to no insulin in type 1 disease, patients must continue insulin injections or pump therapy. Semaglutide's role is to improve insulin efficiency, lower insulin requirements, and reduce blood sugar variability.

What does the clinical evidence say about semaglutide and type 1 diabetes outcomes?

Peer-reviewed trials show that type 1 patients receiving semaglutide alongside insulin achieve HbA1c reductions of 0.5–0.7%, with insulin dose reductions averaging 15–30%. Weight loss of 3–5 kg and reduced hypoglycemia frequency have also been documented. Safety data confirms semaglutide is well-tolerated in this population when insulin doses are properly adjusted.

How much does semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injection starts at $149/month, with no insurance required and HSA/FSA eligibility available. Your dose may need to go up as your treatment progresses, but your price won't. All medications come from licensed 503A compounding pharmacies and PlexusDx serves all 50 states.

Is semaglutide safe for type 1 diabetes patients?

Yes, when used with proper medical supervision and insulin adjustment. The primary safety consideration is hypoglycemia risk during titration; your provider must lower insulin doses as semaglutide is introduced. Nausea and gastrointestinal side effects are common initially but typically resolve within weeks. Rare but serious risks include pancreatitis and thyroid concerns, making baseline screening and follow-up monitoring essential.

How can the PlexusDx Precision Peptide Genetic Test help me?

The test analyzes your GLP1R, GIPR, and FTO genetic variants—among 150+ insights—to predict your individual semaglutide response and optimize your therapy. Patients with favorable GLP1R variants may achieve stronger results at lower doses, while FTO variants correlate with greater weight-loss potential. This personalized insight helps your provider tailor dose and compound selection for maximum benefit.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves